✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Molybdenum is an investigational drug.
There have been 12 clinical trials for Molybdenum. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2016.
The most common disease conditions in clinical trials are Hepatolenticular Degeneration, Metal Metabolism, Inborn Errors, and Syndrome. The leading clinical trial sponsors are Alexion Pharmaceuticals, Alexion Pharma GmbH, and Origin Biosciences.
There are forty-eight US patents protecting this investigational drug and five hundred and thirty international patents.
Recent Clinical Trials for Molybdenum
|Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants||Alexion Pharmaceuticals||Phase 1|
|Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840||Alexion Pharmaceuticals||Phase 2|
|Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.||Alexion Pharmaceuticals||Phase 1|
Top disease conditions for Molybdenum
Top clinical trial sponsors for Molybdenum
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Molybdenum||See Plans and Pricing||Shaped catalyst for sour gas shift reactions and methods for using them||Clariant Corporation (Louisville, KY)||See Plans and Pricing|
|Molybdenum||See Plans and Pricing||Composite hollow particle, a method for making thereof, and a method for producing hydrogen gas||King Abdulaziz University (Jeddah, SA)||See Plans and Pricing|
|Molybdenum||See Plans and Pricing||Process for producing N-phosphonomethylglycine||Monsanto Company (St. Louis, MO)||See Plans and Pricing|
|Molybdenum||See Plans and Pricing||Overbased additives for lubricant oils containing a molybdenum complex, process for preparing them and compositions containing the said additives||Societe Nationale Elf Aquitaine (Courbevoie, FR)||See Plans and Pricing|
|Molybdenum||See Plans and Pricing||Apparatus for injection analysis of total inorganic phosphate||Calgon Corporation (Pittsburgh, PA)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Molybdenum||China||CN105665030||2034-12-08||See Plans and Pricing|
|Molybdenum||Austria||AT82576||2007-10-26||See Plans and Pricing|
|Molybdenum||Australia||AU2430288||2007-10-26||See Plans and Pricing|
|Molybdenum||Australia||AU594589||2007-10-26||See Plans and Pricing|
|Molybdenum||Brazil||BR8805503||2007-10-26||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|